Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma

Trial Profile

Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results (n=35, Data cut off: Jan 16, 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 12 Sep 2017 Results (n=6) assessing efficacy and safety, presented at the 42nd European Society for Medical Oncology Congress.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top